The Institute of Pharmaceutical Research and Technology (IFET), received today the first batches of drug dosages of companies Regeneron-Roche against Covid-19, based on monoclonal antibodies. Specifically, 2,000 doses of this medicine were taken, in the context of Greece’s participation in the European Union program (contract SANTE-C3-2020-091) for the supply of the new treatment.
The drug is available for the first time in Greece by IFET. The Administration and the services of the Institute moved quickly, following the order of the Ministry of Health, in order to ensure in time the installments corresponding to our country. The drug has been safely stored in the specially designed infrastructure of the Institute, until it receives the necessary approval for its disposal.
It is clarified that the goal of this treatment is to prevent the worsening of the disease. The administration of the treatment to the patients will be carried out based on criteria that are expected to be determined by the competent bodies, while IFET will follow the instructions of the Ministry of Health for the effective distribution and delivery of the doses.
Ioannis Sotiriou, CEO of IFET, stated in this regard: “IFET acted immediately and effectively to ensure in our country the corresponding doses of the drug monoclonal antibodies. The Institute has always focused on the Greek patient and the defense of public health. We fully understand the social role of the Institute and with an absolute sense of responsibility we proceed to its transformation into a modern provider of innovative solutions to the final beneficiaries, the Greek patients “.
.
